Author

M. Highkin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Iliuk· 1 shared A. R. Tipton· 1 shared B. Zhou· 1 shared I. S. Hagemann· 1 shared J. L. Prior· 1 shared J. R. Edwards· 1 shared N. Vemalapally· 1 shared R. Bose· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Iliuk

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21/CDK4/6/Cyclin D1 axis driving tumorigenesis and drug resistance.

X. Cheng, Y. Sun, M. Highkin, N. Vemalapally, X. Jin, B. Zhou, J. L. Prior, A. R. Tipton, S. Li, A. Iliuk, S. Achilefu, I. S. Hagemann, J. R. Edwards, R. Bose

This study investigates how HER2 V777L and PIK3CA H1047R mutations drive breast cancer tumorigenesis and drug resistance, showing effective combination therapies.

bioRxiv · Nov 9, 2022 · PreprintCancer Biology